1	Louisiana Administrative Code			
2 3	Title 46 – Professional and Occupational Standards			
4 5	Part LIII: Pharmacists			
6 7	Cha	apte	er 24. Limited Service Providers	
8 9	Sul	- ncha	npter E. Marijuana Pharmacy	
10				
11	§24	40.	Preamble; Warning; Consultation Suggested	
12	A. Pursuant to Act 261 of the Regular Session of the 2015 Louisiana Legislature as well as the subsequent			
13	amendments found in Act 96 of the Regular Session of the 2016 Louisiana Legislature, the Board of Pharmacy			
14		was	s directed to:	
15		1.		
16		2.	Adopt rules relating to the dispensing of recommended marijuana for therapeutic use, with such rules to	
17			include, at a minimum, the following:	
18			a. – d	
19			e. Standards, procedures, and protocols to ensure all recommended therapeutic marijuana dispensed,	
20			with the exception of raw or crude marijuana product, is consistently pharmaceutical grade;	
21			f. – k	
22			l. limitations on dispensing of raw or crude marijuana.	
23	В. –	C		
24				
25	AUT	THOR	AITY NOTE: Promulgated in accordance with R.S. 40:1046.	
26	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1538 (August 2017), amended LR			
27			* * *	
28	<b>§24</b>	43.	Marijuana Products	
29	A.	Exc	clusive Source.	
30		1.	The exclusive source of marijuana products shall be the producers licensed for that activity by the	
31			Department of Agriculture and Forestry (LDAF).	
32		2.	That Licensed producers shall prepare pharmaceutical grade marijuana products as well as raw marijuana	
33			products for distribution to the marijuana pharmacies licensed by the board.	
34		3.	···	
35	B.	Lab	poratory Testing	
36		1.		
37		2.	A producer shall make available each such batch at the production facility for testing by a laboratory	
38			approved by LDAF. The laboratory employee shall select a random sample from each batch.	

39		a.	Medical marijuana concentrate shall not be used to produce any final product until it has passed all
10			analysis limits for:
11			i. – v
12		b.	Product shall not be released for delivery to a marijuana pharmacy for sale or consumption until it
13			has passed all concentrate analysis limits for:
14			i. – iii
15		<u>c.</u>	Final products not produced from concentrate, e.g., dried and cured flower) shall not be released for
16			delivery to a marijuana pharmacy for sale or consumption until it has passed all analysis limits for:
17			i. active ingredient analysis for characterization of potency;
18			ii. pesticide active ingredients, including but not limited to the most recent list of targeted
19			pesticides published by LDAF;
50			iii. heavy metals;
51			iv. mycotoxins;
52			v. microbiological contaminants; and
53			vi. homogeneity.
54		<u>e</u> <u>d</u>	LDAF personnel may select a random sample at any point in the process for the purpose of analysis
55			for anything the LDAF deems necessary.
56		<u>d</u> <u>e</u>	e. Samples shall be secured in a manner approved by LDAF at all times when not in immediate use for
57			the analyses being conducted.
58	3.		
59	4.	Tes	sting Specifications
50		a	- c.iv
51		d.	With respect to the pesticide chemical residue test, a marijuana sample shall be deemed to have
52			passed if it satisfies the most stringent acceptable standard for a pesticide chemical residue in any
53		4	food item as set forth in Subpart C of the United States Environmental Protection Agency's
54			"Tolerances and Exemptions for Pesticide Chemical Residues in Food" as found in 40 CFR 180 or it
55			successor does not contain any residues not appearing on LDAF's approved list and any approved
66			residues present are less than the limits allowed by LDAF.
57		e.	
58		f.	With respect to the test for homogeneity, a marijuana sample shall be deemed <u>passed if each aliquot</u>
59			tested is within plus or minus 15 percent of the total aliquots average finding for potency for each
70			labeled active ingredient. Any solid product will be considered not homogenous to have failed if 10
71			percent of the sample product contains more than 20 percent of the total active ingredient.
72		g.	Every sample shall undergo an active ingredient analysis or potency analysis.
73			i i.(d)
74			ii. For product samples, the potency test is to establish the active ingredient composition for

110

A. A marijuana pharmacy shall:

75	verification of labeling to ensure accurate dosing. The maximum variance permitted is 15 percent
76	from the labeled amount. For example, a product labeled as containing 10 milligrams of
77	tetrahydrocannabinol (THC) shall contain no less than 8.5 milligrams THC and no more than 11.5
78	milligrams THC. For final products containing THCA, the total THC determined shall also be
79	within the variance allowed for the THC as labeled.
80	B.5. – B.8
81	C. Product Dosage Forms.
82	1. The producer shall limit their production of pharmaceutical grade marijuana products to the following
83	dosage forms:
84	a. – c
85	d. Gelatin-based or pectin-based chewables;
86	e. – h
87	i. Bulk raw product.
88	2. The producer may produce other products from raw or crude marijuana, including dried flower, buds and
89	other plant material, intended for the following methods of administration:
90	a. Combustible forms for inhalation, including but not limited to pre-rolls; and
91	b. Edible forms for ingestion.
92	2 3. No marijuana product shall:
93	a. include alcoholic liquor, dietary supplements, or any drug, except for pharmaceutical grade
94	marijuana. For purposes of this provision, alcoholic liquor does not include any liquid or solid
95	containing less than 0.5 percent of alcohol by volume, or ethanol-based tinctures.
96	b. be manufactured or sold as a beverage.
97	e b. be manufactured or sold in a form or with a design that:
98	i. – iv
99	d c. have had pesticide chemicals or organic solvents used during the production or manufacturing
100	process other than those which may be approved by the commissioner of LDAF.
101	3 4. Any marijuana product not in compliance with the provisions of this Paragraph Section shall be deemed
102	adulterated.
103	D. – E.4.f
104	
105	AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.
106	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1540 (August 2017), amended LR
107	45:1473 (October 2019), LR 46:568 (April 2020), amended LR 46:1227 (September 2020), LR 47:590 (May 2021), <u>LR</u>
108	* * *
109	§2453. Security Requirements for Marijuana Pharmacies

111	$13. \ldots$
112	4. keep all approved safes and vaults securely locked and protected from entry, except for the actual time
113	required to remove or replace marijuana, provided that during hours of operation the pharmacist-in-charge
114	may authorize the placement of a limited quantity of dispensing stock outside such safes or vaults but
115	within the secure prescription department.
116	A.5. – H
117	
118	AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.
119	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1548 (August 2017), amended LR
120	* * *
121	§2457. Standards of Practice
122	A. – D.5
123	E. Professional Practice Standards
124	1. Recommendation / opinion / referral (hereinafter "request") for Therapeutic Marijuana
125	1.a. – 1.b.vii
126	c. Requests for marijuana products shall expire one year after the date of issue, unless a shorter period
127	of time is indicated by the physician. A pharmacist may dispense marijuana product on multiple
128	occasions as indicated by the physician and as needed by the patient until the request expires;
129	however, the pharmacist shall not dispense more than a 90-day supply of marijuana product at one
130	time nor more than a one year supply of marijuana product pursuant to a single request. A
131	pharmacist shall not dispense marijuana product pursuant to an expired request.
132	d. Requests for raw or crude marijuana products intended for persons under 21 years of age shall
133	specifically indicate a recommendation for raw or crude forms of marijuana for such persons.
134	de. A marijuana pharmacy shall transfer an unexpired request for marijuana product to another
135	marijuana pharmacy when requested by the patient or his caregiver.
136	2. <u>Dispensing Marijuana Products</u>
137	<u>a</u> . Prior to dispensing any marijuana product to a patient, the pharmacist shall review the patient's
138	records in the state prescription monitoring program. The pharmacist shall resolve any concerns
139	identified in that review by consultation with the recommending physician.
140	b. Dispensing Limitations
141	i. A pharmacist shall not dispense more than two and one-half ounces, or 71 grams, of raw or
142	crude marijuana every 14 days to any person.
143	ii. Subject to the above limitation on dispensing raw or crude marijuana products, a pharmacist
144	may dispense marijuana products on multiple occasions as indicated by the physician and
145	needed by the patient until the request expires; however, the pharmacist shall not dispense mor
146	than a 90-day supply of marijuana product at one time nor more than a one-year supply

Regulatory	Daga a a a 1	2021 T	Darr	Manimana	Duadriata
Keguiatory	Proposai	2021-1	J∼ Kaw	Marijuana	Products

Draft #6

147	pursuant to a single request.
148	E.3. – E.6.e.iv
149	
150	AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.
151	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1550 (August 2017), amended LR
152	45:1473 (October 2019), LR 47:246 (February 2021), LR 47:1111 (August 2021), LR
153	

